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Background. *e use of Integra Dermal Reconstruction Template has emerged as an option for wound reconstruction, after
resection of congenital nevi, especially giant congenital nevi. *ere have been many reports on Integra use in the literature for this
purpose. *is systematic review with pooled analysis examines the current literature regarding Integra use after resection of
congenital nevi, including patient characteristics and reported outcomes.Methods. Systematic electronic searches were performed
using PubMed, Ovid, Embase, and Cochrane library databases for studies reporting the use of Integra to reconstruct defects after
nevi resection. Studies were analyzed if they met the inclusion criteria. Pooled descriptive statistics were performed. Results.
*irteen studies that met the inclusion criteria were included for analysis, yielding 31 procedures in 31 patients. Eleven of the
thirteen studies were case reports representing 17 of the 31 patients. One study was retrospective, and the other study was a
prospective study.*e mean follow-up was 2.67 years (range, 0.2–13 years). *e overall wound closure rate was 100%.*e overall
initial Integra take rate was 90.3% and the skin graft take rate was 100%.*e rate of reported complications was 14.8%.*e average
age of patients was 7.36 years. *e average size of the nevus was 6.29% TBSA (range, 0.005%–26%), and the time to definitive skin
grafting was 3.28 weeks. Significant heterogeneity was found among the published studies.Conclusion. We conclude that the use of
Integra appears to be a safe and viable option for defect reconstruction after the primary or secondary excision of congenital nevi
of different sizes and on most parts of the body. Long-term follow-up studies and prospective cohort studies are required in order
to fully estimate the incidence of complications. However, the rarity of this condition make these types of studies very difficult.
1. Introduction
Congenital melanocytic nevi (CMN) are benign proliferations
of melanocytic cells in the epidermis or dermis.*e estimated
incidence of CMN in the general population is in the vicinity
of 1 to 2 percent [1]. *e incidence of giant hairy melanocytic
melanoma, a subset of CMN, is even rarer. A major concern
regarding patients with CMN is the possibility of developing
melanoma. *ere is irrefutable evidence in the literature to
support the increased risk of developing melanoma in in-
dividuals with CMN compared with the general population. A
systematic review conducted by Krengel et al. in 2006 found
the incidence of melanoma to be 0.7 percent in patients with
CMN [2]. Another study in 2005 by Bett showed a 2.9 percent
incidence of melanoma in patients with garment large CMN
and 0.3 percent in patients with head and neck large CMN [3].
*e risk of melanoma has been associated with the size of
the nevus. Giant CMN, CMN greater than 20 cm in size, carry
the greatest risk of melanoma transformation [2]. Patients
with CMN are often referred to plastic surgeons for excision
due to cosmetic concerns and the associated risk of malignant
degeneration. *e recommended treatment for these lesions
is complete resection of the involved skin and tissue [4].
*e surgical treatment of CMN can be very challenging
depending on the size and location of the lesion. Resection of
CMN, especially medium or giant CMN, can leave a sizeable
defect that often requires major reconstructive surgery.
Techniques available include local tissue rearrangement,
Hindawi
Surgery Research and Practice
Volume 2019, Article ID 9483627, 5 pages
https://doi.org/10.1155/2019/9483627
full-thickness skin grafting (FTSG), and split-thickness skin
grafting (STSG) as well as tissue expansion with subsequent
defect closure in at least two-step procedures. Free tissue
transfer can also be used as part of the reconstructive ladder.
*e Integra bilayer wound matrix was developed in the
early 1980s by Yannas et al. [5, 6]. Since its introduction, it
has been used in a variety of wound reconstructions [7].
*ere have also been reports of Integra use in wound re-
construction after resection of CMN. Some of the reported
advantages of Integra include less donor site morbidity
compared to FTSG, STSG, and major flap reconstruction as
well as decreased rate of wound contracture and hyper-
trophic scars. *e purpose of this study was to review the
current literature on the use of Integra for reconstruction
after resection of CMN and to analyze patient characteristics
and outcomes using pooled data analysis.
2. Methods
2.1. Search Methodology. Electronic searches were per-
formed using the PubMed, Ovid, Embase, and Cochrane
library databases for studies reporting on the application of
Integra for congenital nevus reconstruction. *e search
keywords and terms include the following: “nevus,” “nevus
surgery,” and “Integra.” All studies published up to February
2019 were thoroughly reviewed and the references of those
articles were reviewed for additional relevant studies.
2.2. Selection Criteria. *e inclusion and exclusion criteria
were defined before the initiation of data collection. Studies
that reported on the use of Integra for reconstruction of
defects after resection of CMNwere included. Retrospective,
prospective, and case reports published in peer-reviewed
journals were included. Figure 1 outlines the selection
process. *e case reports must include at least the size of the
lesion or a picture of the lesion, the type of skin coverage
used, and the outcome of wound closure. If not, it was
excluded. Studies were also excluded if they were not written
in English, or were commentaries, reviews, or letters.
2.3. Data Collection and Analysis. *e literature search, data
extraction, and assessment of inclusion were conducted by
two of the authors (JO and KH) with uncertainties resolved
through discussion. *e following data were collected: au-
thor, publication year, type of study, and number of patients.
*e primary data collected from the articles included the age
of the patient at the time of resection and Integra appli-
cation, gender, size of the lesion expressed as percentage
total body surface area (%TBSA). For the cases where the
size of the lesion was not reported in %TBSA, the patient’s
image was reviewed, and the size of the lesion was converted
to %TBSA using the Lund and Brower chart. We also
collected data on the location of the lesion and the initial
Integra take rate, defined as incorporation of the Integra
without the need for reapplication. *e type of skin graft
coverage used was collected along with the initial skin graft
take rate, which was defined as graft integration without the
need for regrafting. We also collected data on complications,
if reported, the time of follow-up, and data on whether the
wound achieved eventual closure without using other rescue
modalities, such as local flaps, regrafting, or wound VAC
therapy.
3. Results
*irteen studies were included in the analysis. Table 1
presents the characteristics of the studies that were in-
cluded in the analysis. Almost all the reported cases were
case reports, accounting for 54.8% of the patients
[4, 9–16, 18, 19]. Of the remaining studies, one was retro-
spective [17] and one study was a prospective study [8]. *e
thirteen studies yielded 31 procedures in 31 patients. In
terms of follow-up, 2 of the studies did not report any follow-
up period [16, 17]. Most of the studies indicated whether or
not there were any complications, but three of the studies did
not mention the presence or absence of any complications
[13, 14, 16]. Furthermore, 4 studies did not report the time
from Integra placement to skin grafting [10, 13, 16, 17].
Table 2 represents the patient characteristics and re-
ported outcomes.*e average age was 6.97± 8.00 years, with
58.1% of patients being males and 41.9% being females. *e
trunk was the highest reconstructed area (51.9%), followed
by the extremities (32%) and the face (16.1%). *e average
size of nevus resected was 6.29± 5.73%TBSA, with a range of
0.005–26% TBSA. *e initial Integra take rate was 90.3%.
*e average time from Integra placement to skin grafting
was 3.28± 0.83 weeks.
*e initial Integra take rate was 90.3%, with an initial
skin graft take rate of 100%. Skin grafting was achieved with
mostly split-thickness skin graft in 83.9%, but one study
utilized full-thickness skin graft, representing 6.5% of the
grafts [17], and 2 studies used cultured epithelial autografts,
representing 9.7% of the grafts [10, 16]. Complete wound
closure and healing occurred in 100% of the patients.
Complication rate was 14.8%. *e mean follow-up was 2.56
years (range, 0.2–13 years).
4. Discussion
*is literature review included 13 unique studies yielding 31
procedures involving the application of Integra after re-
section of congenital nevi. *e data extracted in the review is
best estimated from large prospective studies; however, these
data are rare. *e first reported case of Integra for this
purpose was in 2003 by Kopp et al. [11, 12]. Since then, there
have been a few reported cases in the English literature. Most
of the reported cases are case reports with a single pro-
spective study. *ere was significant heterogenicity in the
reported cases. All the cases reported on the age of the
patient, location of the lesion, initial Integra take, type of
skin graft, initial skin graft take, and results of wound
healing. *e size of the lesions was reported using diameter
measurement in some cases and %TBSA in others. Some
cases did not mention the size of the lesion but provided a
picture of the lesion. Not all studies reported on the time
from Integra placement to skin grafting, follow-up time, and
complication rate.
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*e average age of the resection and reconstruction was
7.36 years. Almost all the cases were performed on pediatric
patients, except for one adult patient. *is observation is in
line with the recommended early resection of the lesions in
childhood. Majority of the lesions in this review were located
on the trunk, followed by the extremities, then head, and
neck. *is is in accordance with the reported distribution of
congenital nevus on the body [20]. Based on %TBSA, lesions
greater than 2% TBSA are classified as giant CMN [21]. *e
average size of the resected lesions in this study was 6.29%
TBSA, with the largest reported lesion of 26% TBSA and the
smallest lesion of about 0.005% TBSA. Based on this, one can
infer that the average lesion reconstructed with Integra is a
giant congenital nevus. It also demonstrates that Integra is
feasible in the reconstruction of small defects created by
excision of CMN as well.
Loss of Integra integration is a reported complication of
the use of Integra. We defined the initial Integra take rate as
any amount of Integra take that does not require reap-
plication of the whole or part of the Integra to achieve
optimum closure. Our pooled analysis showed an Integra
take rate of 90.3%. For studies that reported the time to skin
grafting, the average time of Integra application to the
application of skin graft was 3.28 weeks. Although most of
the skin grafts were STSG (83.9%), FTSG and CEA were also
applied successfully to achieve complete wound closure.
Once the skin graft was applied, there was a 100% initial take
rate. All the wound achieved complete healing with a mean
follow-up of 2.56 years.
For the studies that reported any form of complication,
the combined complication rate was 14.8%, including 1
infection, 1 Integra nonintegration, 1 skin regrafting, and 1
hypertrophic scar.
A systematic review conducted by Vourc’h-Jourdain
et al. found out that the risk of developing melanoma from
large CMN was about 1 in 20,00 to 1 in 50,000 and that the
treatment of these lesions should not be generalized but
rather individualized. *is individual assessment should
take into consideration the risk of malignant transformation
as well as psychosocial and esthetic issues [22].
Table 1: Characteristics of the included studies.
References Type of study Year of publication Number of patients
Schiestl et al. [8] Prospective 2009 12
Ramasamy and Jeffery [9] Case report 2008 1
Ozerdem et al. [10] Case report 2003 1
Kopp et al. [11] Case report 2003 1
Kumbla et al. [12] Case report 2015 2
Maguire et al. [13] Case report 2017 1
Barcot et al. [14] Case report 2017 1
Alrawi and Jeffery [15] Case report 2009 2
Earle and Marshall [16] Case report 2005 2
Grunwaldt et al. [17] Retrospective 2013 2
Abai et al. [4] Case report 2004 4
Marano et al. [18] Case report 2015 1
Tønseth et al. [19] Case report 2016 1
13 records excluded
14 full text articles assessed for
eligibility
1 full text excluded
13 full text articles included in 
the analysis
(1) 1 prospective study
(2) 1 retrospective study
(3) 11 case reports/case series
31 records identified through
database searching (PubMed,
Embase, Ovid, and Cochrane databases)
2 additional records identified through
other sources
27 records after duplicate removed
Figure 1: Flow chart of the literature search.
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*ere are several limitations in this review and analysis.
Only case reports, prospective studies, and retrospective
studies were included in the analysis. *ere were no ran-
domized controlled studies reported on this topic. More-
over, the quality of reporting in the included case reports was
generally low. Some studies did not report on any com-
plications. In spite of all these limitations, the combined data
demonstrated the potential viability and safety of Integra in
reconstruction of defects created after excision of CMN.
Conflicts of Interest
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Table 2: Pooled data from all 13 included studies.
Patient Age(yrs) Gender Site
Size (%
TBSA)
Initial
Integra
take rate
Time to
skin graft
(weeks)
Type of
skin
coverage
Follow-
up time
(yrs)
Initial
skin graft
take rate
Complete
wound
healing
Complications
Schiestl
et al. [8]
2.2 F Face 2 Yes 3.1 STSG 4.08 Yes Yes None
11.0 F Face 3 Yes 3.1 STSG 4 Yes Yes None
8.3 F Trunk 2 Yes 2.7 STSG 3.6 Yes Yes None
3.5 F Trunk 10 No 4.3 STSG 0.08 Yes Yes Infection
0.6 F Trunk 2 No 2.7 STSG 2.92 Yes Yes No Integratake
0.8 M Trunk 12 Yes 2.1 STSG 2.35 Yes Yes None
3.8 M Arm 3 Yes 3 STSG 2 Yes Yes None
2.5 M Leg 3 No 2.7 STSG 1.5 Yes Yes None
1.2 M Face 1 Yes 3.1 STSG 1.35 Yes Yes None
9.7 F Trunk 4 Yes 2.9 STSG 1.15 Yes Yes None
2.3 F Arm 4 Yes 2.3 STSG 0.75 Yes Yes None
1.5 F Trunk 6 Yes 3 STSG 0.5 Yes Yes None
Tønseth
et al. [19] 1.5 M Trunk 16 Yes 3 STSG 0.2 Yes Yes Regrafting
Ramasamy
and Jeffery
[9]
17.0 M Trunk 10 Yes 6 STSG 0.8 Yes Yes None
Ozerdem
et al. [10] 6.0 M Trunk 6 Yes — CEA 0.08 Yes Yes None
Kopp et al.
[11] 44.0 F Trunk 12 Yes 2.9 STSG 2.5 Yes Yes None
Kumbla
et al. [12]
5.5 F Hands/arm 2 Yes 3 STSG 1 Yes Yes None
3.7 F Hands/arm 2 Yes 3 STSG 1 Yes Yes None
Maguire
et al. [13] 0.4 F Trunk 26 Yes — STSG 5 Yes Yes —
Barcot et al.
[14] 9.0 F Leg/foot 5 Yes 3 STSG 2.7 Yes Yes —
Alrawi and
Jeffery [15]
13.0 M Trunk 16 Yes 4 STSG 13 Yes Yes None
12.0 M *igh/leg 12 Yes 4 STSG 13 Yes Yes None
Earle and
Marshall
[16]
7.0 F *igh 3 Yes — CEA — Yes Yes —
8.0 M Trunk 12 Yes — CEA — Yes Yes —
Grunwaltd
et al. [17]
11.0 M Nose 0.005 Yes — FTSG — Yes Yes None
7.0 F Nose 0.005 Yes — FTSG — Yes Yes None
Abai et al.
[4]
2.8 F Leg 4 Yes 4 STSG 0.5 Yes Yes None
13.0 M Leg 4 Yes 4 STSG 1 Yes Yes None
10.0 F Trunk 4 Yes 4 STSG 2 Yes Yes None
8.0 F Trunk 6 Yes 4 STSG 1.1 Yes Yes None
Marano
et al. [18] 2.0 M Trunk 3 Yes 2 STSG 1 Yes Yes
Hypertrophic
scar
Totals
Mean:
7.36 yrs
SD:
7.99 yrs
M:
77%
F:33%
Trunk:
51.6%
Extremities:
32.3%
Face: 16.1%
Mean:
6.29%
TBSA
SD:
5.73%
TBSA
90.30%
Mean:
3.28wks
SD:
0.83wks
STSG:
83.9%
FTSG:
6.5%
CEA:
9.7%
Mean:
2.56 yrs
SD:
3.22 yrs
100% 100% 14.8%
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Excluded studies and literature search strategy. (Supple-
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